Skip to main content

Advertisement

Contact Naoki Kumashiro

From: Rationale and design of study of dapagliflozin versus sitagliptin treatment efficacy on prevention of cardiovascular risk factors in type 2 diabetes patients: the DIVERSITY-CVR study

Contact corresponding author